Arcutis Biotherapeutics, Inc. ARQT Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $376.07M+91.3% | $196.54M+230% | $59.61M+1,517% | $3.69M— | ||
| $36.7M+91.8% | $19.13M+284% | $4.99M+561% | $754K— | ||
| $339.38M+91.3% | $177.41M+225% | $54.62M+1,763% | $2.93M— | ||
| 90.2%0.0pp | 90.3%-1.4pp | 91.6%+12.1pp | 79.5%— | ||
| $77.05M+0.8% | $76.42M-30.9% | $110.58M-39.4% | $182.44M+25.3% | ||
| $274.55M+19.7% | $229.39M+23.9% | $185.15M+51.6% | $122.12M— | ||
| $388.3M+19.5% | $324.94M+8.1% | $300.71M-1.5% | $305.31M+47.8% | ||
| —— | -$128.4M+46.7% | -$241.1M+20.1% | -$301.63M-46.0% | ||
| $12.08M-55.5% | $27.17M-8.6% | $29.71M+89.8% | $15.65M— | ||
| —— | —— | -$15.19M-54.5% | -$9.83M— | ||
| $1.17M+81.0% | $647K-78.8% | $3.05M— | —— | ||
| —— | -$140.04M+46.6% | -$262.14M+15.8% | -$311.46M-50.9% | ||
| —— | -$1.15+69.7% | -$3.79+32.4% | -$5.61-34.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s revenue?
- Arcutis Biotherapeutics, Inc. (ARQT) generated $415.6M in revenue over the trailing twelve months, up 95.3% year over year.
- Is Arcutis Biotherapeutics, Inc. profitable?
- Arcutis Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $44.8M over the trailing twelve months, a -13.9% net margin.
- What are Arcutis Biotherapeutics, Inc.'s profit margins?
- Gross margin is 90.9% and operating margin is -12.0%, with a -13.9% net margin.
- What is Arcutis Biotherapeutics, Inc.'s earnings per share?
- Arcutis Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.36.
- Where does Arcutis Biotherapeutics, Inc.'s income statement data come from?
- Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
